Logo image of GOVX

GEOVAX LABS INC (GOVX) Stock Price, Quote, News and Overview

NASDAQ:GOVX - Nasdaq - US3736786068 - Common Stock - Currency: USD

1.71  -0.12 (-6.56%)

After market: 1.8 +0.09 (+5.26%)

GOVX Quote, Performance and Key Statistics

GEOVAX LABS INC

NASDAQ:GOVX (3/7/2025, 8:00:01 PM)

After market: 1.8 +0.09 (+5.26%)

1.71

-0.12 (-6.56%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High11.18
52 Week Low1.09
Market Cap16.14M
Shares9.44M
Float9.39M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-12 2025-05-12
IPO04-04 1994-04-04


GOVX short term performance overview.The bars show the price performance of GOVX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40

GOVX long term performance overview.The bars show the price performance of GOVX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of GOVX is 1.71 USD. In the past year, price decreased by -19.72%.

GEOVAX LABS INC / GOVX Daily stock chart

GOVX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.17 378.30B
AMGN AMGEN INC 16.39 174.51B
GILD GILEAD SCIENCES INC 25.47 146.22B
VRTX VERTEX PHARMACEUTICALS INC 1683.76 125.39B
REGN REGENERON PHARMACEUTICALS 15.5 77.34B
ARGX ARGENX SE - ADR 231.21 36.10B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 31.66B
ONC BEIGENE LTD-ADR N/A 26.47B
BNTX BIONTECH SE-ADR N/A 26.08B
BIIB BIOGEN INC 9.13 22.01B
NTRA NATERA INC N/A 19.02B
GMAB GENMAB A/S -SP ADR 25.15 15.34B

About GOVX

Company Profile

GOVX logo image GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is headquartered in Smyrna, Georgia and currently employs 17 full-time employees. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.

Company Info

GEOVAX LABS INC

1900 Lake Park Drive, Suite 380

Smyrna GEORGIA 30080 US

CEO: David A. Dodd

Employees: 17

Company Website: https://www.geovax.com/

Phone: 16783847220

GEOVAX LABS INC / GOVX FAQ

What is the stock price of GEOVAX LABS INC today?

The current stock price of GOVX is 1.71 USD. The price decreased by -6.56% in the last trading session.


What is the ticker symbol for GEOVAX LABS INC stock?

The exchange symbol of GEOVAX LABS INC is GOVX and it is listed on the Nasdaq exchange.


On which exchange is GOVX stock listed?

GOVX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for GEOVAX LABS INC stock?

11 analysts have analysed GOVX and the average price target is 14.89 USD. This implies a price increase of 770.88% is expected in the next year compared to the current price of 1.71. Check the GEOVAX LABS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GEOVAX LABS INC worth?

GEOVAX LABS INC (GOVX) has a market capitalization of 16.14M USD. This makes GOVX a Nano Cap stock.


How many employees does GEOVAX LABS INC have?

GEOVAX LABS INC (GOVX) currently has 17 employees.


What are the support and resistance levels for GEOVAX LABS INC (GOVX) stock?

GEOVAX LABS INC (GOVX) has a support level at 1.45 and a resistance level at 1.84. Check the full technical report for a detailed analysis of GOVX support and resistance levels.


Should I buy GEOVAX LABS INC (GOVX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GEOVAX LABS INC (GOVX) stock pay dividends?

GOVX does not pay a dividend.


When does GEOVAX LABS INC (GOVX) report earnings?

GEOVAX LABS INC (GOVX) will report earnings on 2025-05-12.


What is the Price/Earnings (PE) ratio of GEOVAX LABS INC (GOVX)?

GEOVAX LABS INC (GOVX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.97).


What is the Short Interest ratio of GEOVAX LABS INC (GOVX) stock?

The outstanding short interest for GEOVAX LABS INC (GOVX) is 8.12% of its float. Check the ownership tab for more information on the GOVX short interest.


GOVX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

GOVX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to GOVX. While GOVX seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GOVX Financial Highlights

Over the last trailing twelve months GOVX reported a non-GAAP Earnings per Share(EPS) of -18.97. The EPS decreased by -42.1% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -218.88%
ROE -286.01%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%81.04%
Sales Q2Q%N/A
EPS 1Y (TTM)-42.1%
Revenue 1Y (TTM)-100%

GOVX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to GOVX. The Buy consensus is the average rating of analysts ratings from 11 analysts.


Ownership
Inst Owners3.07%
Ins Owners0.81%
Short Float %8.12%
Short Ratio1.19
Analysts
Analysts81.82
Price Target14.89 (770.76%)
EPS Next Y78.27%
Revenue Next YearN/A